Murphy Nicole
Head of Pharm Ops and Tech
Murphy Nicole has filed 2 SEC Form 4 filings (7 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Feb 17, 2026.
On the most recent filing, Murphy Nicole is listed as Head of Pharm Ops and Tech at BIOGEN INC. Inside the rolling window, Murphy Nicole reported 1 open-market purchase totaling $585 in BIIB and no open-market sales.
Companies traded
Other insiders at BIIB
Insider Buying
$585
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Murphy Nicole made?
Murphy Nicole has filed 2 SEC Form 4 filings (7 transaction rows) across 1 company since 2026.
Which companies does Murphy Nicole trade?
Murphy Nicole has filed SEC Form 4 disclosures for 1 company, including BIIB.
When was Murphy Nicole's most recent SEC Form 4 filing?
Murphy Nicole's most recent SEC Form 4 filing on Tracefour is dated Feb 17, 2026.
What is Murphy Nicole's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Murphy Nicole is listed as Head of Pharm Ops and Tech.
What is Murphy Nicole's total buy and sell value in the current window?
Inside the rolling retention window, Murphy Nicole bought $585 and sold $0 based on SEC Form 4 filings.
What was Murphy Nicole's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 3 BIIB shares on 2026-02-12, worth $585, per SEC Form 4 filings.